Related Experiment Video
Updated: Oct 2, 2025
Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
LncRNA MALAT1 functions as a biomarker of no-reflow phenomenon in ST-segment elevation myocardial infarction patients
Xiheng Yang1, Rixin Dai2, Zhong Qin2
1Department of Cardiology, Affiliated Hospital of Guilin Medical University, 15#, Lequn Road, Guilin, 541001, Guangxi, China. yangxiheng541001@163.com.
Abstract:
MALAT1 was reported to sponge miR-30e, miR-126 and miR-155 in the pathogenesis of many diseases. Plasma miR-30e can indicate the risk of no-reflow during primary percutaneous coronary intervention (pPCI), while miR-126 can be used as a predictor of coronary slow flow phenomenon. In this study, we compared the diagnostic value of above genes in the prediction of no-reflow phenomenon in ST-segment elevation myocardial infarction (STEMI) subjects receiving pPCI. Quantitative real-time PCR, ELISA, Western blot and luciferase assays were performed to explore the regulatory relationship of MALAT1/miR-30e, MALAT1/miR-126, MALAT1/miR-155, miR-126/HPSE, and miR-155/EDN1. ROC analysis was carried out to evaluate the potential value of MALAT1, miRNAs and target genes in differentiating normal reflow and no-reflow in STEMI patients receiving pPCI. Elevated MALAT1, CRP, HPSE, and EDN1 expression and suppressed miR-30e, miR-155 and miR-126 expression was found in the plasma of STEMI patients receiving pPCI who were diagnosed with no-reflow phenomenon. ROC analysis showed that the expression of MALAT1, miR-30e, miR-126 and CRP could be used as predictive biomarkers to differentiate normal reflow and no-reflow in STEMI patients receiving pPCI. MALAT1 was found to suppress the expression of miR-30e, miR-126 and miR-155, and HPSE and EDN1 were respectively targeted by miR-126 and miR-155. This study demonstrated that MALAT1 could respectively sponge the expression of miR-30e, miR-126 and miR-155. And miR-30e, miR-126 and miR-155 respectively targeted CRP, HPSE and EDN1 negatively. Moreover, MALAT1 could function as an effective biomarker of no-reflow phenomenon in STEMI patients receiving pPCI.
Insights
Long non-coding RNA MALAT1 sponges miR-30e, miR-126, and miR-155, impacting no-reflow after percutaneous coronary intervention in ST-segment elevation myocardial infarction patients. MALAT1 serves as a predictive biomarker for this complication.
Area of Science:
- Cardiovascular Biology
- Molecular Biology
- Biomarkers
Background:
- The no-reflow phenomenon complicates primary percutaneous coronary intervention (pPCI) in ST-segment elevation myocardial infarction (STEMI).
- MicroRNAs (miRNAs) like miR-30e and miR-126 have shown potential in predicting cardiovascular events, including no-reflow and coronary slow flow.
- Long non-coding RNAs (lncRNAs) are increasingly recognized for their roles in disease pathogenesis, with MALAT1 implicated in sponging various miRNAs.
Purpose of the Study:
- To investigate the diagnostic value of MALAT1, miR-30e, miR-126, and miR-155 in predicting the no-reflow phenomenon in STEMI patients undergoing pPCI.
- To explore the regulatory relationships between MALAT1, specific miRNAs (miR-30e, miR-126, miR-155), and their target genes (CRP, HPSE, EDN1).
Main Methods:
- Quantitative real-time PCR and ELISA were used to measure the expression levels of MALAT1, miRNAs, and target genes in STEMI patients with and without no-reflow.
- Western blot and luciferase assays were employed to elucidate the regulatory mechanisms between MALAT1, miRNAs, and target genes.
- Receiver Operating Characteristic (ROC) analysis was performed to assess the predictive value of the identified biomarkers.
Main Results:
- STEMI patients with no-reflow exhibited elevated plasma levels of MALAT1, CRP, HPSE, and EDN1, alongside suppressed levels of miR-30e, miR-126, and miR-155.
- ROC analysis indicated that MALAT1, miR-30e, miR-126, and CRP are potential biomarkers for differentiating normal reflow from no-reflow in STEMI patients.
- Experimental assays confirmed that MALAT1 sponges miR-30e, miR-126, and miR-155, and that miR-126 and miR-155 target HPSE and EDN1, respectively.
Conclusions:
- MALAT1 acts as a sponge for miR-30e, miR-126, and miR-155, contributing to the no-reflow phenomenon in STEMI patients undergoing pPCI.
- The identified miRNAs, miR-30e, miR-126, and miR-155, negatively regulate CRP, HPSE, and EDN1, respectively.
- MALAT1 demonstrates potential as a valuable biomarker for predicting the no-reflow phenomenon in STEMI patients receiving pPCI.
